The case study involved a 61-year-old obese Caucasian male with a medical history of smoking, hypertension, chronic obstructive pulmonary disease, and sleep apnea who initially presented to the hematology clinic with polycythemia.
A recent report described the surprising finding of an abdominal aortic aneurysm (AAA) and renal cell carcinoma in a patient with secondary polycythemia and normal erythropoietin (EPO) levels.
The authors said the finding was surprising given the amount of literature that associates elevated EPO levels with renal cell carcinoma.
The case study involved a 61-year-old obese Caucasian male with a medical history of smoking, hypertension, chronic obstructive pulmonary disease (COPD), and sleep apnea, who initially presented to the hematology clinic with polycythemia. The patient did not report any significant symptoms or a history of blood clots; physicians identified a large renal mass suspicious for renal cell carcinoma of the right kidney after a computerized tomography (CT) and ultrasound.
Renal cell cancer usually presents with a palpable mass, hematuria, and flank pain, the authors wrote, but about 10% to 40% of patients show paraneoplastic syndromes, particularly hypercalcemia, hypertension, and polycythemia, with the renal cell carcinoma hiding and affecting multiple organs from a primary cancer.
The patient had his aorta repaired and underwent a radical nephrectomy; preoperative hemoglobin and erythropoietin level was 18.3 g/dL and 8.5 IU/L respectively, which normalized to a hemoglobin level of 13.1 g/dL within 2-3 days post-surgery. Measured hemoglobin months afterward was 12.0 g/dL.
“Surgical removal of the renal cell carcinoma and repair of surrounding vasculature successfully resolve most complications. Specifically, it is unknown whether serum EPO levels correlate with the severity of renal cell carcinoma evaluated through the TNM,” the authors said. “Given the rising interest and reports of surgical complications of concomitant conditions with renal cell carcinoma, more investigation into the mechanism, occurrence, and additional risk factors posed by these paraneoplastic syndromes secondary to renal cell carcinoma remains open to investigation.”
The researchers concluded that further investigation into paraneoplastic syndromes secondary to renal cell carcinoma is necessary.
Reference
Kopel J, Sharma P, et al. Polycythemia with renal cell carcinoma and normal erythropoietin level [published online December 11, 2019]. Case Rep Urol. doi: 10.1155/2019/3792514.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen